In a published study in The Indian Practitioner, India’s premier medical journal, vitamin K2-7 was reported for the first time to alleviate intensity of symptoms of clinically confirmed peripheral neuropathy, characterized by the colloquial “pins and needles” throbbing pain and weakness and numbness in extremities.
 
This open-labeled clinical study, registered with Clinical Trial Registry of India (CTRI), was conducted with 30 men and women, 18 to 60 years old, with peripheral neuropathy, divided into a moderate pain group with a VAS score of 6 to 8, and a severe pain group with a VAS score of 8-9.  (VAS is the Visual Analog Scale which assesses intensity of symptoms). Each participant of the study took 100 mcg vitamin K2-7 twice a day for 9 weeks. The vitamin used was in form of 100 mcg gelatin capsules of vitamin K2-7 (MenaquinGold) provided by Synergia Life Sciences Pvt. Ltd. (A Viridis Group of Companies).  
 
The VAS score in both groups reduced significantly at the study’s conclusion from the baseline score of up to 9 to 1 to 2 score after 9 weeks of vitamin K2-7. Study participants reported reduction in tingling, numbness, weakness, fatigue and intensity of muscle cramps.
 
Peripheral neuropathy, a condition that can cause bouts of intense discomfort, is a common problem faced by a large segment of the population, and is multifactorial in origin including nutritional deficiencies, metabolic and age related degenerative conditions.
 
“This study shows outstanding potential for vitamin K2 menaquinone-7 (K2-7) for growing population who suffer from peripheral neuropathy, which reduces the quality of life and productivity. Persistence of neuropathy symptoms despite routine approach is a well identified unmet health care need,” said Dr. Dilip Mehta, CEO and chairman of Viridis Pvt. Ltd. Group of Companies.